Position in LGVN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$133,829
-$59,252 QoQ
Shares Held
190,370
+2.5% QoQ
Ownership
0.597%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#6
of 39 holders
Holding Since
Dec 2021
5 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in LGVN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026JANE STREET GROUP, LLC holds $1,364,130,252 across 291 Biotechnology names. LGVN ranks #187 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | BBIO |
BridgeBio Pharma, Inc.
|
2,934,193 | $218,538,693 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
191,541 | $102,847,939 | |
| 3 | AXSM |
Axsome Therapeutics, Inc.
|
403,995 | $98,885,855 | |
| 4 | TGTX |
Tg Therapeutics, Inc.
|
1,752,646 | $96,290,370 | |
| 5 | EXEL |
Exelixis, Inc.
|
1,402,438 | $76,306,651 | |
| 6 | QURE |
uniQure N.V.
|
1,610,483 | $74,178,846 | |
| 7 | HALO |
Halozyme Therapeutics, Inc.
|
694,684 | $54,372,915 | |
| 8 | TVTX |
Travere Therapeutics, Inc.
|
938,699 | $53,327,489 |
All Filings in LGVN
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $133,829 | 190,370 | Shares | Defined | 2026-08-14 | |
| 2026-03-31 | $193,081 | 185,656 | Shares | Defined | 2026-05-12 | |
| 2025-09-30 | $32,956 | 43,942 | Shares | Defined | 2025-11-14 | |
| 2024-12-31 | $35,452 | 20,493 | Shares | Defined | 2025-02-14 | |
| 2021-12-31 | $696,933 | 57,741 | Shares | Defined | 2022-02-15 | |
| No filing history on record for this holder in this stock. | ||||||